July 16, 2023, 12:08PM GMT+0200
Amelia Turp
Actualitate
I write about real estate, constructions, transportation, health, and sometimes about the business of textiles and fashion. Got any news tips? Drop me an email at amelia.turp@forbes.ro.
An experimental Alzheimer’s drug developed by Acumen Pharmaceuticals that targets a new form of the toxic protein beta-amyloid in the brain has passed a first safety test and will move on to a larger study, it has announced company Sunday.
The drug, ACI193, was well tolerated in the first human trial, the company said. The results of the randomized, placebo-controlled trial of 62 patients with early Alzheimer’s disease were presented at the Alzheimer’s Association International Conference in Amsterdam.
Acumen’s drug targets and binds to amyloid beta oligomers, a toxic, soluble version of the amyloid protein that forms brain plaques associated with the memory-destroying disease, Dr. Eric Siemers, Acumen’s chief medical officer, said in an interview.
The target is similar to that of the recently approved Leqembi, developed by Biogen and Eisai, which attacks another soluble, toxic form of the protein in the brain. Leqembi won standard U.S. approval earlier this month after showing it can remove amyloid plaques and slow the progression of Alzheimer’s disease in early-stage patients.
2023-07-16 07:08:40
#Acumen #Pharmaceuticals #Alzheimers #drug #passed #initial #safety #test #Forbes.ro
